To find the use of warm oxygen therapy in diabetic patients with ulcers
Phase 1
- Conditions
- Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications
- Registration Number
- CTRI/2020/01/023004
- Lead Sponsor
- Yostra Labs Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Individuals with type 2 diabetes mellitus and non-healing diabetic foot ulcer for 3 months or more
Exclusion Criteria
foot ulcers of other pathology, individuals who are referred for surgical
interventions
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does warm oxygen therapy (KADAM) from Yostra Labs target in E116 diabetic foot ulcer healing dynamics?
How does KADAM compare to standard-of-care treatments like debridement and offloading in E116 Type 2 diabetes patients with foot ulcers?
What are the primary clinical endpoints in CTRI/2020/01/023004 Phase 1 trial of KADAM for E116 diabetic foot ulcer healing?
Which biomarkers predict response to warm oxygen therapy (KADAM) in E116 diabetic foot ulcer patients with Type 2 diabetes mellitus?
Are there other oxygen-based therapies or compounds being studied for E116 diabetic foot ulcers alongside Yostra Labs' KADAM?